
|Articles|March 12, 2014
- Immunotherapy (Issue 2)
- Volume 2
- Issue 1
The Outlook for CAR-Modified T Cells
Author(s)Renier J. Brentjens, MD, PhD
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the outlook for CAR-modified T cells.
Advertisement
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the outlook for CAR-modified T cells.
Read more about CAR-modified T cells and other immunotherapies for B-cell malignancies > >
Articles in this issue
about 12 years ago
B-Cell Malignancies Faring Well With Immunotherapiesabout 12 years ago
Update on Immunotherapy and Targeted Combination Therapiesabout 12 years ago
How Immunotherapies are Changing the Treatment of Melanomaabout 12 years ago
Progress Made With PD-L1 as Predictive Biomarkerabout 12 years ago
Oncolytic Viral Therapies About to Spreadabout 12 years ago
The Future of Immunotherapy Treatments in Lung Cancerabout 12 years ago
Checking in on Checkpoint InhibitorsAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5



































